Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world, and represents a major barrier to sustainable human development. Ischemic heart disease, cerebrovascular disease, cardiomyopathy and heart failure (HF), and hypertension among others represent major forms of CV disease. Heart failure (HF) is among the key contributors to the CV-related health care burden, a uninterrupted concern despite the utilization of clinically tried guideline-directed therapies. The most common cause for HF is reduced left cavum heart muscle perform. ARBs produce equivalent mortality benefits with fewer adverse effects than ACE inhibitors. Angiotensin converting enzyme (ACEI) reduces the combined risk of death or hospitalization, slow progression of HF, and reduced rate of reinfarction. Sacubitril/valsartan could be a first-in-class twin action molecule of the neprilysin (NEP) substance sacubitril (AHU-377) and therefore the angiotensin II (Ang II) sort one (AT1) receptor blocker (ARB) valsartan. The beneficial antihypertensive and HF effects of sacubitril/valsartan are mediated through the inhibition of NEP in catabolizing the natriuretic peptides (NPs) and the blockade of Ang II, AT1 receptor with valsartan. These actions of sacubitril/ valsartan end in general dilation and inflated symptoms and symptoms, resulting in decrease in peripheral tube resistance and plasma volume contraction, all necessary actions for the lowering of BP and improving HF symptoms.
INTRODUCTION
Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world, and represents a major barrier to sustainable human development. Ischemic heart disease, cerebrovascular disease, cardiomyopathy and heart failure (HF), and hypertension among others represent major forms of CV disease. Mortality from CV sickness had plateaued within the recent years rising regarding concerning alarms about the sustained effectivity of obtainable preventive and treatment choices. Heart failure (HF) is among the key contributors to the CV-related health care burden, a dogging concern despite the utilization of clinically verified guidelinedirected therapies [1] .
Heart failure is a clinical syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left cavum heart muscle perform [2] . The incidence and prevalence estimates of HF are unreliable in India because of the lack of surveillance systems to adequately capture these data [3] . HF is classified based on left ventricular ejection fraction (LVEF) into HF with reduced EF (HFrEF) with an LVEF <40% and HF with preserved EF (HFpEF) with an LVEF ≥50%. An EF between 40% and 49% is considered an intermediate zone and is termed as HF with borderline EF or HF with mid-range EF. Epidemiologic data indicate that HFpEF and HFrEF contribute equally to the total HF population. HFpEF patients have a similar postdischarge mortality risk and equally high rates of re-hospitalization, compared to patients with HFrEF [4] .
Some of the major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neurohormonal stimulation, abnormal myocyte calcium cycling, accelerated apoptosis and genetic mutations. There are several medications to treat CHF, including Angiotensin-Converting Enzyme inhibitor (enalapril, captopril), Angiotensin II Receptor Blockers (lorsatan, valsartan), betablocker (atenolol, bisoprolol), diuretics and surgery includes angioplasty. Angiotensin II receptor blockers (ARBs) block the angiotensin II receptor, preventing the deleterious effects of angiotensin II. ARBs produce equivalent mortality benefits with fewer adverse effects than ACE inhibitors. Angiotensin converting enzyme (ACEI) reduces the combined risk of death or hospitalization, slow progression of HF, and reduced rate of reinfarction [2] . Advances in our understanding of the reninangiotensin-aldosterone (RAAS) pathway and natriuretic peptide system, lessons learned from randomized trials of natriuretic peptide system augmentation, and pharmacoinnovation led to the creation and validation of combination sacubitril/valsartan ([LCZ696]) for the treatment of HFrEF [4] .
Sacubitril/valsartan is a first-in-class dual action molecule of the neprilysin (NEP) inhibitor sacubitril (AHU-377) and the angiotensin II (Ang II) type 1 (AT1) receptor blocker (ARB) valsartan. The drug has been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2015 for the treatment of heart failure with reduced ejection fraction [HFrEF] and awaits approval for the treatment of hypertension. The beneficial antihypertensive and HF effects of sacubitril/valsartan are mediated through the inhibition of NEP in catabolizing the natriuretic peptides (NPs) and the blockade of Ang II, AT1 receptor with valsartan. These actions of sacubitril/ valsartan result in systemic vasodilation and increased diuresis and natriuresis, leading to decrease in peripheral vascular resistance and plasma volume contraction, all important actions for the lowering of BP and improving HF symptoms [5] .
REVIEW OF LITERATURE
1) Ramesh R. Dargad et al [3] (2018) conducted a study in patients with hypertension who received sacubitrilvalsartan combination drug. Inclusion of the study was based mainly on the methods section of the trials. When obtainable, large, well-controlled trials with acceptable applied mathematics methodology was most popular. The study was conducted in 8442 adult patient with symptomatic chronic HF and systolic dysfunction. The study shows that sacubitrilvalsartan is more effective in improving symptoms and physical limitations, reducing the risk of cardiovascular death, HF hospitalization, and the overall mortality and morbidity compared to its counterparts.
2) Helena Norberg et al [6] (2018), conducted a study to investigate the eligibility of the prospective comparison of angiotensin receptor-neprilysin inhibitor to determine impact on global mortality and morbidity in heart failure. A retrospective study in 2029 patients was performed, and 401 patients had ejection fraction of < 35%. 95 patients consummated all entering criteria and thus were eligible for sacubitril-valsartan. Only 24% of our real-world HFrEF population was eligible for sacubitril-valsartan, and the real world HFrEF patients were significantly older than the PARADIGM-HF population.
3) Oriol Iborra-Egea et al [7] (2017), the study was sought to explore the mechanistic details for sacubitril-valsartan in heart failure and post-myocardial infarction remodeling, using as in silico, systems biology approach. When analyzed independently, sacubitril was found to attenuate cardiomyocytes cell death, hypertrophy and impaired myocytes contractility by inhibiting PTEN. Valsartan improves cardiac remodeling by inhibiting the guanine nucleotides-binding protein family. 4) Victor shri et al [8] (2017), the study was conducted to determine the clinical benefit for sacubitril-valsartan versus ACE inhibitor enalapril in patients with heart diseases with reduced ejection fraction. Patients were randomized to double daily sacubitril-valsartan 200mg or ACE inhibitors 10mg. The study style incorporated 2 wash out periods (~36h each) to reduce any potential risk of angioedema thanks to overlapping ACE and neprilysin inhibition. Overall 148 suspected angioedema events, 54 were confirmed as angioedema by AAC. The frequency was higher in black patients. Most events were mild. There was no excess risk of angioedema with sacubitril-valsartan versus enalapril. 5) Yandrapalli S e tal [9] (2017), conducted a Phase III double-blind controlled trial in 8442 patients with LVEF< 40% who received twice daily dosing of either 200mg sacubitrilvalsartan or 10 mg enalapril in addition to standard medical therapy for HF. At 27-month follow-up, LCZ696 was associated with 20% reduction in the composite primary end point death from CV causes or hospitalization for HF, compared to enalapril. Sacubitril -valsartan performed higher than ACE inhibitor across varied HFrEF patient characteristics and showed substantial profit in patients with different common co morbidities. 6) Randall.C.Starling [10] (2015), conducted a study in the mean age of 8442 patients in PARADIGM-HF. 93% people were receiving beta blockers and 60% were receiving mineral corticoid receptor antagonist, patient had persistent symptoms and signs of heart failure.
The investigators reported a 20% reduction in the primary outcome of death from cardiovascular causes or hospitalization in patients with heart failure who received sacubitril/valsartan compared with enalapril.
CONCLUSION
Despite the significant advances in the diagnosis and treatment of heart failure, the disease continues to remain at a higher risk of re-hospitalization, mortality and morbidity worldwide. Inspite of the presence of several drugs such as angiotensin-converting enzyme inhibitors, beta blockers, angiotensin receptor blockers and aldosterone antagonists for HF, patients with the illness continue to have a downward spiral due to the disease progression. It can conclude that Sacubitril -valsartan an ARNI represents a major therapeutic advance in the avenue of CV disease, particularly HF. This drug has demonstrated an excellent safety profile, and the drug is purported to become a block-buster for the treatment of HF. The therapeutic effect of the drug has been effective in reducing the risk of cardiovascular death and hospitalization among HF patients with reduced ejection fraction. REFERENCE
